Apr 18,2016

Propeller Partners with AMC Health to Improve Care Management and Outcomes for Chronic Respiratory Disease

Propeller Health, the leading digital health solution for respiratory medicine, and AMC Health, the leading provider of proven remote patient monitoring and engagement solutions that are exclusively endorsed by the American Hospital Association, today announced a partnership to help patients living with chronic obstructive pulmonary disease (COPD) and asthma better manage their disease and reduce symptoms and hospital visits. The multi-year partnership signed in January will launch this month with two commercial programs and a clinical research study investigating adherence barriers at large health plans across the United States.

COLLABORATION PARTNERSHIP

#r&d

View Analyst & Ambassador Comments
Go to original news
May 24,2016

Vectura and Propeller Health announce collaboration to develop digitally-connected inhalers to address chronic respiratory diseases

Vectura Group plc and Propeller Health, the leading digital health solution for respiratory medicine, today announced a collaboration to develop inhalers that combine Vectura’s proven dry powder inhaler (“DPI”) technology with Propeller’s FDA-cleared digital health platform. The initial focus of the collaboration will be the development of an add-on sensor for Vectura’s lever-operated multi-dose inhaler (LOMI). Patients with a Propeller-connected LOMI device will be more engaged with their care and better equipped to understand their disease and improve self-management.

COLLABORATION PARTNERSHIP

#r&d

#connected device

View Analyst & Ambassador Comments
Go to original news
Oct 05,2021

Dignity Health and Propeller Health Bring Asthma and COPD Digital Inhaler Data into EHR

Dignity Health, which is part of 21-state health system CommonSpirit Health, and Propeller Health, a leader in digital health and therapeutics for asthma and chronic obstructive pulmonary disease (COPD), announced today that they have integrated Propeller’s platform into Dignity Health’s electronic health record (EHR) system. Now, the Propeller solution can be ordered and managed through the EHR like any other medication or treatment.

COLLABORATION PARTNERSHIP

#connected device

#rwd

View Analyst & Ambassador Comments
Go to original news
Dec 28,2022

A Korean DTx Company LifeSemantics to Unveil the Redpill Breath Solution for Pulmonary Rehabilitation DTx at CES 2023

On December 28, LifeSemantics (CEO Song Seung-jae), a specialized digital health company, announced that it will join the Consumer Electronics Show 2023 (CES 2023), one of the world's largest IT and appliance expos, to be held in Las Vegas, the United States, in January 2023, to unveil the solution and technology of Redpill Breath, a digital therapeutics (DTx) for patients requiring pulmonary rehabilitation such as chronic obstructive pulmonary disease (COPD).

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 28,2020

Helping low-income students take control of asthma: A Q&A with Dr. Theresa

Children with asthma in low-income areas experience significantly greater healthcare utilization than children in high-income areas. Dr. Theresa Guilbert, a pediatric pulmonologist and director of the Asthma Center at Cincinnati Children’s Hospital, works closely on this issue. She and her team recently completed a first-of-its-kind study, which combined telehealth, in-person visits and Propeller’s digital health platform to help economically disadvantaged students in Cincinnati take control of their asthma. Students received Propeller sensors for their inhalers and used our smartphone app to manage their medication regimen. The study’s outcomes are promising. In six months, the students improved their controller medication adherence by up to 46% and experienced no emergency department visits or hospitalizations — a significant improvement over baseline.

CLINICAL STUDY

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Apr 07,2020

Propeller data shows 14.5% med adherence lift since COVID-19 outbreak began

With hospitals overburdened with COVID-19 cases, it’s essential that patients with asthma and COPD stay home if possible, both to avoid infection and keep emergency rooms free for people experiencing coronavirus symptoms. The data from 7,578 Propeller users shows that patients are taking their preventative health more seriously than ever with the help of our digital health tool. Since the COVID-19 outbreak began to ramp up in January, patients have become 14.5% more adherent to their controller medication regimen, with most of that improvement noted in the last 4 weeks.

CLINICAL STUDY

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 22,2020

Digital health drives positive changes in behavior for people with respiratory conditions

Propeller Health presents the its latest findings on patient behavior from the users benefiting Propeller mobile app. In a study group of 3,511 adults with asthma and 1,159 adults with COPD who used Propeller to manage their condition, engagement with the Propeller mobile app was associated with significant increases in adherence to controller medications, which are crucial to keeping symptoms under control.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 07,2020

Novartis, Propeller Health co-package new asthma treatment

Novartis and respiratory health company Propeller Health, a ResMed subsidiary, have teamed up to co-package the latter’s digital health platform with the pharma giant’s new asthma medication Enerzair Breezhaler. This news come shortly after the product landed European Commission clearance. The co-packaged product will be launching in the EU during 2020. However, it is not yet available in the U.S. Propeller’s sensor is able to attach to the Enerzair Breezhaler inhaler, where it can collect medication data and send that information to a corresponding app.

COLLABORATION PARTNERSHIP

#product & service

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 18,2020

NuvoAir respiratory platform receives Class Im medical device status

Sweden-based digital therapeutics respiratory company, NuvoAir, has been certified as a Class Im medical device. The NuvoAir Home platform includes Air Next, a certified bluetooth spirometer, a connected patient app and a healthcare portal. Patients can use the platform to self-monitor their respiratory health and share clinically relevant data with their care teams, who can view this data remotely via a healthcare portal.

REGULATORY CE MARK

#connected device

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 03,2020

How digital health can reveal if a patient’s asthma or COPD is under control

Digital health tools are used to track patient health data over time and provide insight into important trends overlooked when looking at single data points during a patient’s visit with a healthcare provider. The data collected by these tools has great potential when integrated with the patient’s clinical care. Propeller’s research team has been digging into this topic and recently presented their findings at the 2020 European Respiratory Society (ERS) International Congress, which was virtual this year due to the coronavirus pandemic.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Subscribe to RESPIRATORY